高剂量放化疗增加直肠癌患者保器官机会并获得满意功能结局
回顾性分析2006年4月至2017年7月接受根治性盆腔放疗的非转移性直肠腺癌患者57例,中位放疗剂量80 Gy,42例(73.7%)达临床完全缓解,3年总生存率91.4%,中位随访43.5个月。高剂量放化疗显示出有希望的生存结局、可接受的近期和远期不良反应及满意的长期功能结局和生活质量。
要点
- 57例非转移性直肠腺癌患者接受中位80 Gy放疗联合同期氟尿嘧啶类化疗,42例(73.7%)达临床完全缓解。
- 3年局部无复发生存率77.3%,3年无远处转移生存率79.2%,3年总生存率91.4%。
- 肿瘤距肛缘≤3 cm患者括约肌保留率85.3%;21例完成生活质量问卷者总体健康状况评分78.57±17.59。
核心结论
- 高剂量放化疗显示出有希望的生存结局、可接受的近期和远期不良反应以及满意的长期功能结局和生活质量,作者认为可考虑作为拒绝手术的直肠癌患者的非侵入性替代选择。
研究设计与样本
- 回顾性研究纳入2006年4月至2017年7月接受根治性盆腔放疗的非转移性直肠腺癌患者57例,中位年龄59.0岁(范围29-84岁)。
- 分期为I期5例(8.8%)、II期16例(28.1%)、III期36例(63.2%);53例(93.0%)肿瘤位于距肛缘5 cm以内。
- 全部患者接受氟尿嘧啶类同期放化疗,中位放疗剂量80 Gy(范围60-86 Gy);生存分析采用Kaplan-Meier法,生活质量和功能结局采用EORTC生活质量问卷评估。
主要发现
- 42例(73.7%)在放化疗后达临床完全缓解;3-4级不良反应共发生于18例(31.6%)患者。
- 中位随访43.5个月(范围14.9-163.2个月)后,12例(21.1%)出现局部进展,11例(19.3%)发生远处转移。
- 3年局部无复发生存率77.3%(95% CI 65.7-88.8%),3年无远处转移生存率79.2%(95% CI 68.2-90.2%),3年无进展生存率61.9%(95% CI 48.8-75.0%),3年癌症特异性生存率93.1%(95% CI 85.8-100.0%),3年总生存率91.4%(95% CI 83.6-99.2%)。
- 肿瘤距肛缘3 cm以内患者末次随访时括约肌保留率为85.3%;远期不良反应主要为肛门出血。
- 完成生活质量问卷的21例患者总体健康状况评分为78.57±17.59,其中95.2%报告无尿失禁,85.7%报告无大便失禁。
临床怎么用
- 作者认为,对于拒绝手术的直肠癌患者,高剂量放化疗可考虑作为非侵入性替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High dose chemoradiotherapy offers a curative chance for patients with rectal cancer that are unfit or unwilling to undergo surgical resection, yet its long-term survival and functional outcomes have been rarely investigated. METHODS: Patients with non-metastatic rectal adenocarcinoma who received pelvic radiation for curative intent from April 2006 to July 2017 were retrospectively investigated. Survival rates were analyzed using the Kaplan-Meier method. Quality of life and functional outcomes were evaluated using the EORTC quality of life questionnaire. RESULTS: A total of 57 patients were included, with a median age of 59.0 (range, 29-84) years. The numbers of patients who were diagnosed as stage I, II and III were 5 (8.8%), 16 (28.1%) and 36 (63.2%), respectively. 53 (93.0%) patients had tumor located within 5 cm from the anal verge. All patients received fluorouracil-based concurrent chemoradiotherapy with a median radiation dose of 80 (range, 60-86) Gy. All kinds of grade 3-4 adverse events occurred in 18 (31.6%) patients. 42 (73.7%) patients achieved a clinical complete response after chemoradiotherapy. After a median follow-up of 43.5 (range 14.9-163.2) months, 12 (21.1%) patients had local progression and 11 (19.3%) developed distant metastasis. The 3-year local recurrence-free survival and distant metastasis-free survival were 77.3% (95% CI, 65.7-88.8%) and 79.2% (95% CI, 68.2-90.2%), while the 3-year progression-free survival, cancer-specific survival, overall survival were 61.9% (95% CI, 48.8-75.0%), 93.1% (95% CI, 85.8-100.0%) and 91.4% (95% CI, 83.6-99.2%), respectively. For patients who had tumor located within 3 cm from the anal verge, the sphincter preservation rate was 85.3% at last follow-up. Long-term adverse events mainly were anal blood loss. 21 patients completed the quality-of-life questionnaire and had a score of the global health status of 78.57 ± 17.59. Of them, 95.2% reported no urinary incontinence and 85.7% reported no fecal incontinence. CONCLUSIONS: High dose chemoradiation demonstrated promising survival outcomes with acceptable short-term and long-term side effects, and satisfying long-term functional outcomes and quality of life. It could be considered as a non-invasive alternative for rectal cancer patients who refuse surgery.
引用
- Wang QX, Zhang S, Xiao WW, et al. High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer. Radiat Oncol. 2022. PMID: 35585551. doi:10.1186/s13014-022-02066-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。